Cargando…

The Role of Early Molecular Response in the Management of Chronic Phase CML

PURPOSE OF REVIEW: Although tyrosine kinase inhibitors (TKIs) spectacularly improve the disease burden and the overall survival of chronic myeloid leukemia patients, early identification of a subset of poor TKI responders has been recognized as a critical goal to prevent disease progression in these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrington, Patrick, Kizilors, Aytug, de Lavallade, Hugues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Chronic Myeloid Leukemias (J Pinilla-Ibarz, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410202/ https://www.ncbi.nlm.nih.gov/pubmed/28405921 http://dx.doi.org/10.1007/s11899-017-0375-0

Ejemplares similares

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

CML-384 Immunological Response to SARS-CoV-2 After Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients – A Prospective Study
por: Galvis, Marisol Miranda, et al.
Publicado: (2022)

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
por: Harrington, Patrick, et al.
Publicado: (2023)

CML-005: Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with a Donor and Recipient with SARS-CoV-2 Infection
por: Ali, Gadallah, et al.
Publicado: (2021)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

NGS in CML - New standard diagnostic procedure?
por: Branford, Susan, et al.
Publicado: (2019)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
por: Burchert, Andreas
Publicado: (2014)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
por: Dulucq, Stéphanie, et al.
Publicado: (2022)

Chronic Myeloid Leukemia Stem Cell Biology
por: Crews, Leslie A., et al.
Publicado: (2012)

The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
por: Patterson, Shaun David, et al.
Publicado: (2023)

CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries
por: Matsuzaki, Mika, et al.
Publicado: (2023)

Impact of the Covid-19 Pandemic on Quality of Life of Patients with CML
por: Wysoglad, Hubert, et al.
Publicado: (2021)

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
por: Flynn, Kathryn E., et al.
Publicado: (2022)

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022)

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
por: Shanmuganathan, Naranie, et al.
Publicado: (2023)

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
por: Fiordi, Benedetta, et al.
Publicado: (2023)

Treatment-Free Remission: the New Goal in CML Therapy
por: Atallah, Ehab, et al.
Publicado: (2021)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Role of Epigenetics in Chronic Myeloid Leukemia
por: Machova Polakova, Katerina, et al.
Publicado: (2013)

Management of Chronic Myeloid Leukemia in Children and Young Adults
por: Ford, Maegan, et al.
Publicado: (2022)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience
por: Pagnano, Katia B, et al.
Publicado: (2020)

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
por: Claudiani, Simone, et al.
Publicado: (2020)

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia
por: Rabian, Florence, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication
por: Shahrin, Nur Hezrin, et al.
Publicado: (2022)

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
por: Bonifacio, Massimiliano, et al.
Publicado: (2020)

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study
por: Pagnano, Katia B, et al.
Publicado: (2021)

Milestones and Monitoring
por: Morotti, Alessandro, et al.
Publicado: (2015)

What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
por: Delgado, Nancy, et al.
Publicado: (2022)

Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina Yu., et al.
Publicado: (2021)

A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients
por: Fechio, Leonardo, et al.
Publicado: (2021)

Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina Yu., et al.
Publicado: (2021)

Early response evaluation in AML using mass cytometry
por: Gjertsen, Bjørn T., et al.
Publicado: (2019)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_12ssgf85oi7r0dlro6vn3eb67q